SLC5A2 and kidney disorder: Together, these trials, meta-analyzed with the CVOTs and heart failure trials, found clear superiority of SGLT2 inhibitors compared with placebo, with a relative risk reduction of 40% for kidney disease progression in patients with or without type 2 diabetes (13).